FDA OKs Nivolumab in Metastatic CRC Subtype FDA OKs Nivolumab in Metastatic CRC Subtype

The FDA has given accelerated approval to nivolumab for the treatment of microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news